OTCMCLPBY
Market cap24bUSD
Dec 20, Last price
11.09USD
1D
1.93%
1Q
-17.86%
Jan 2017
64.78%
Name
Coloplast A/S
Chart & Performance
Profile
Coloplast A/S develops and sells intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Interventional Urology, Voice and Respiratory Care, and Wound & Skin Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, hand cleanser, and odor control products, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, it offers voice and respiratory products, including medical devices for neck stoma under the Provox brand; and products for tracheostoma under the TRACOE brand. The company was founded in 1954 and is headquartered in Humlebæk, Denmark.
Valuation
Title DKK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2024‑09 | 2023‑09 | 2022‑09 | 2021‑09 | 2020‑09 | 2019‑09 | 2018‑09 | 2017‑09 | 2016‑09 | 2015‑09 | |
Income | ||||||||||
Revenues | 27,030,000 10.33% | 24,500,000 8.51% | 22,579,000 16.23% | |||||||
Cost of revenue | 20,480,000 | 17,677,000 | 15,718,000 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | 6,550,000 | 6,823,000 | 6,861,000 | |||||||
NOPBT Margin | 24.23% | 27.85% | 30.39% | |||||||
Operating Taxes | 1,343,000 | 1,242,000 | 1,421,000 | |||||||
Tax Rate | 20.50% | 18.20% | 20.71% | |||||||
NOPAT | 5,207,000 | 5,581,000 | 5,440,000 | |||||||
Net income | 5,052,000 5.62% | 4,783,000 1.64% | 4,706,000 -2.47% | |||||||
Dividends | (4,720,000) | (4,247,000) | (4,041,000) | |||||||
Dividend yield | 2.40% | 2.64% | 2.45% | |||||||
Proceeds from repurchase of equity | 500,000 | 9,134,000 | (619,000) | |||||||
BB yield | -0.25% | -5.67% | 0.37% | |||||||
Debt | ||||||||||
Debt current | 5,338,000 | 7,345,000 | 1,853,000 | |||||||
Long-term debt | 18,278,000 | 13,116,000 | 17,560,000 | |||||||
Deferred revenue | 199,000 | |||||||||
Other long-term liabilities | 155,000 | 6,000 | 396,000 | |||||||
Net debt | 22,726,000 | 19,446,000 | 18,948,000 | |||||||
Cash flow | ||||||||||
Cash from operating activities | 2,766,000 | 4,226,000 | 5,099,000 | |||||||
CAPEX | (1,346,000) | (1,241,000) | (1,135,000) | |||||||
Cash from investing activities | (1,336,000) | (8,957,000) | (11,759,000) | |||||||
Cash from financing activities | (1,518,000) | 5,265,000 | 6,591,000 | |||||||
FCF | (9,062,000) | 14,539,000 | (297,000) | |||||||
Balance | ||||||||||
Cash | 788,000 | 911,000 | 633,000 | |||||||
Long term investments | 102,000 | 104,000 | (168,000) | |||||||
Excess cash | ||||||||||
Stockholders' equity | 17,942,000 | 14,860,000 | 5,602,000 | |||||||
Invested Capital | 40,726,000 | 29,400,000 | 26,054,000 | |||||||
ROIC | 14.85% | 20.13% | 29.96% | |||||||
ROCE | 15.16% | 21.65% | 24.39% | |||||||
EV | ||||||||||
Common stock shares outstanding | 224,900 | 215,500 | 212,800 | |||||||
Price | 875.00 17.04% | 747.60 -3.63% | 775.80 -22.92% | |||||||
Market cap | 196,787,500 22.15% | 161,107,800 -2.41% | 165,090,240 -23.07% | |||||||
EV | 219,513,500 | 181,709,800 | 184,533,240 | |||||||
EBITDA | 7,840,000 | 7,892,000 | 7,791,000 | |||||||
EV/EBITDA | 28.00 | 23.02 | 23.69 | |||||||
Interest | 882,000 | 638,000 | 172,000 | |||||||
Interest/NOPBT | 13.47% | 9.35% | 2.51% |